TherapeuticsMD (NASDAQ:TXMD) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note issued to investors on Sunday. The firm issued a hold rating on the stock.

TherapeuticsMD Stock Performance

TXMD opened at $1.66 on Friday. The business has a 50 day moving average of $1.99 and a 200-day moving average of $2.17. TherapeuticsMD has a 52 week low of $1.61 and a 52 week high of $4.35.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Friday, May 10th. The company reported ($0.07) earnings per share (EPS) for the quarter. The business had revenue of $0.31 million during the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in TherapeuticsMD stock. ADAR1 Capital Management LLC bought a new position in TherapeuticsMD, Inc. (NASDAQ:TXMD) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 272,160 shares of the company’s stock, valued at approximately $612,000. ADAR1 Capital Management LLC owned approximately 2.57% of TherapeuticsMD at the end of the most recent quarter. 30.74% of the stock is owned by institutional investors.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.